Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [507]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“and a molecular replacement solution for the 1FD6-ZM109 data set consisting of two unbound PG9 Fab molecules per asymmetric unit was obtained using PHASE”
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Anatomy and Taxonomy of Protein Structure
Richardson, J. S. (1981) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60520-3 · Cited by 3,375
Research works printed but not linked: 2
- Zolla-Pazner S V2-reactive antibodies in RV144 vaccinees’ plasma AIDS Res Hum Retroviruses 27 A-21 2011
- Otwinowski, Z. & Minor, W. in Methods Enzymol. Vol. 276, 307–326 (Academic Press, 1997)
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by specific antibodies, such as that seen on the surface of the HIV virion (507) (508) (509) 594) .”
BackgroundImmune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808
Self-citationFUBAR: A Fast, Unconstrained Bayesian AppRoximation for Inferring Selection
Murrell, B., Moola, S., Mabona, A., Weighill, T., Sheward, D., Kosakovsky Pond, S. L., & Scheffler, K. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst030 · Cited by 1,358
“Several potent and broadly crossneutralizing HIV antibodies (PG9/ PG16-like and PGT128-like antibodies) are dependent on both a peptide and a glycan component for binding (McLellan et al. 2011; Pejchal et al. 2011), providing a precedent for this mode of recognition.”
BackgroundStructure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Self-citationCrystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
Julien, J.-P., Cupo, A., Sok, D., Stanfield, R. L., Lyumkis, D., Deller, M. C., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., et al. (2013) · Science · doi:10.1126/science.1245625 · Cited by 797
“Antibody interactions additional to those previously described in the PG9/PG16-V1/V2-scaffold co-crystal structures (4, 6) are predicted to occur with gp120 V3, as well as with residues N160 and N197 of the adjacent protomer.”
BackgroundInfluentialSelf-citationStructure and immune recognition of trimeric pre-fusion HIV-1 Env
Pancera, M., Zhou, T., Druz, A., Georgiev, I. S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G.-Y., Ofek, G., et al. (2014) · Nature · doi:10.1038/nature13808 · Cited by 740
Self-citationDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Self-citationCryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
Lyumkis, D., Julien, J.-P., de Val, N., Cupo, A., Potter, C. S., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., Carragher, B., et al. (2013) · Science · doi:10.1126/science.1245627 · Cited by 669
Self-citationBarouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Self-citationPeptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
Burton, D. R., & Hangartner, L. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055515 · Cited by 583
“The contact residues for PG9 are blue (99); PGT122 dark purple (22); PGT128 light purple (96); PGT135 medium purple (136); VRC01 green (88); b12 olive green, from alanine scan (160); PGT151 dark red (98); 8ANC195 medium red (86, 87); and 35O22 light red (24).”
BackgroundSelf-citationComplex-type N -glycan recognition by potent broadly neutralizing HIV antibodies
Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J. F., Halper-Stromberg, A., Gnanapragasam, P. N. P., Spencer, D. I. R., Seaman, M. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217207109 · Cited by 550
“Black dashed and solid lines show positive (10-188) and negative (mG053) controls, respectively.”
BackgroundInfluentialKlein, F., Diskin, R., Scheid, J. F., Gaebler, C., Mouquet, H., Georgiev, I. S., Pancera, M., Zhou, T., Incesu, R.-B., Fu, B. Z., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.018 · Cited by 537
Self-citationHIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Klein, F., Halper-Stromberg, A., Horwitz, J. A., Gruell, H., Scheid, J. F., Bournazos, S., Mouquet, H., Spatz, L. A., Diskin, R., Abadir, A., et al. (2012) · Nature · doi:10.1038/nature11604 · Cited by 500
HIV-1 neutralizing antibodies induced by native-like envelope trimers
Sanders, R. W., van Gils, M. J., Derking, R., Sok, D., Ketas, T. J., Burger, J. A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. (2015) · Science · doi:10.1126/science.aac4223 · Cited by 496
“The basis for the design of the BG505 V1V2-scaffold protein has also been described (57).”
BackgroundSelf-citationConformational dynamics of single HIV-1 envelope trimers on the surface of native virions
Munro, J. B., Gorman, J., Ma, X., Zhou, Z., Arthos, J., Burton, D. R., Koff, W. C., Courter, J. R., Smith, A. B., Kwong, P. D., et al. (2014) · Science · doi:10.1126/science.1254426 · Cited by 492
Self-citationKiss, G., Çelebi‐Ölçüm, N., Moretti, R., Baker, D., & Houk, K. N. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201204077 · Cited by 492
B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2197 · Cited by 486
Self-citationCross-neutralization of influenza A viruses mediated by a single antibody loop
Ekiert, D. C., Kashyap, A. K., Steel, J., Rubrum, A., Bhabha, G., Khayat, R., Lee, J. H., Dillon, M. A., O’Neil, R. E., Faynboym, A. M., et al. (2012) · Nature · doi:10.1038/nature11414 · Cited by 481
“In this analysis, residues are considered conserved if substitutions are restricted to other amino acids in the same group: (1) Asp, Asn, Glu, Gln (negatively charged or isosteric polar substitutions); (2) Val, Ile, Leu, Met (small hydrophobic); (3) Phe and Tyr (aromatic); and (4) Ser and Thr (small polar/hydroxyl).”
Self-citationHIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
“mAbs PG9 and PG16, and subsequent mAbs in this category, such as CH01-04 and PGT141-145 (82, 83, 109) bind to relatively conserved residues within V2 and require major interactions with surface glycans, most importantly an N-linked glycan at position 160 (131, 132).”
BackgroundSelf-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Kwong, P. D., & Mascola, J. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.012 · Cited by 455
“All of the V1V2-directed broadly neutralizing antibodies identified to date appear to have extended anionic heavy-chain third-complementarity-determining regions (CDR H3s) (McLellan et al., 2011; Pancera et al., 2010b; Pejchal et al., 2010; Walker et al., 2009, 2011), though differences in CDR H3 length, tyrosine sulf…”
InfluentialSelf-citationAntibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
“Structural analyses showed that these antibodies penetrate the glycan shield with a long anionic CDRH3 that contacts a β-strand on gp120, and interacts with N-linked glycans from two adjacent gp120 protomers in the trimeric envelope complex (59, 60).”
BackgroundBroad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
Huang, J., Kang, B. H., Pancera, M., Lee, J. H., Tong, T., Feng, Y., Imamichi, H., Georgiev, I. S., Chuang, G.-Y., Druz, A., et al. (2014) · Nature · doi:10.1038/nature13601 · Cited by 420
Self-citationIncreased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Rolland, M., Edlefsen, P. T., Larsen, B. B., Tovanabutra, S., Sanders-Buell, E., Hertz, T., deCamp, A. C., Carrico, C., Menis, S., Magaret, C. A., et al. (2012) · Nature · doi:10.1038/nature11519 · Cited by 417
Self-citationBurton, D. R., Poignard, P., Stanfield, R. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1225416 · Cited by 415
Self-citationTrimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
Stewart-Jones, G. B. E., Soto, C., Lemmin, T., Chuang, G.-Y., Druz, A., Kong, R., Thomas, P. V., Wagh, K., Zhou, T., Behrens, A.-J., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.010 · Cited by 404
“…glycan N262, in which the GlcNAc stem associates with the protein surface) (Kong et al., 2015) or from glycans bound by antibody (Kong et al., 2013; McLellan et al., 2011; Pejchal et al., 2011), which interrupt branch interactions that provide the dominant form of glycan-glycan contact (Figure 3C).”
InfluentialSelf-citationAntibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Self-citationLiao, H.-X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K.-K., Chen, X., Tsao, C.-Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.011 · Cited by 377
“(C) Structure of bnAb PG9 in complex with the V1-V2 domain from HIV-1 strain CAP45 (PDB ID: 3U4E) (McLellan et al., 2011).”
BackgroundMethodInfluentialSelf-citationSok, D., van Gils, M. J., Pauthner, M., Julien, J.-P., Saye-Francisco, K. L., Hsueh, J., Briney, B., Lee, J. H., Le, K. M., Lee, P. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415789111 · Cited by 364
“Interestingly, although these three antibodies show similar overall binding affinities, we measured a faster off-rate for PGDM1403 than for PGT145 and PGDM1400.”
BackgroundInfluentialSelf-citationFalkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C., Ramirez, A., Derking, R., van Gils, M. J., Liang, C.-H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.009 · Cited by 359
“These regions are the high-mannose gp120 patch around N332, recognized by antibodies such as 2G12, PGT121, and PGT128, and the V2 loop region around N160, recognized by antibodies such as PG9 and PG16 (Doores and Burton, 2010; McLellan et al., 2011; Walker et al., 2011; Julien et al., 2013b; Kong et al., 2013b).”
InfluentialSelf-citationPrevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Hraber, P., Seaman, M. S., Bailer, R. T., Mascola, J. R., Montefiori, D. C., & Korber, B. T. (2014) · AIDS · doi:10.1097/qad.0000000000000106 · Cited by 357
Self-citationFusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody
Kong, R., Xu, K., Zhou, T., Acharya, P., Lemmin, T., Liu, K., Ozorowski, G., Soto, C., Taft, J. D., Bailer, R. T., et al. (2016) · Science · doi:10.1126/science.aae0474 · Cited by 345
Self-citationDo Kwon, Y., Pancera, M., Acharya, P., Georgiev, I. S., Crooks, E. T., Gorman, J., Joyce, M. G., Guttman, M., Ma, X., Narpala, S., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3051 · Cited by 345
Self-citationSupersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
Kong, L., Lee, J. H., Doores, K. J., Murin, C. D., Julien, J.-P., McBride, R., Liu, Y., Marozsan, A., Cupo, A., Klasse, P.-J., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2594 · Cited by 337
“83 percent of the protein-protein buried surface involves side chains on gp120 (Supplementary Table 2) in contrast to PG9 and PGT 128 that rely primarily on backbone interactions with V1-V2 and V3, respectively, to form main-chain β - strand associations 13,14 .”
Self-citationBlattner, C., Lee, J. H., Sliepen, K., Derking, R., Falkowska, E., de la Peña, A. T., Cupo, A., Julien, J.-P., van Gils, M., Lee, P. S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.008 · Cited by 332
“The quaternary-specific bnAb PGT145 (Walker et al., 2011) did facilitate purification of some JR-FL EnvDCT trimers, but the yield was lower.”
BackgroundInfluentialSelf-citationdeCamp, A., Hraber, P., Bailer, R. T., Seaman, M. S., Ochsenbauer, C., Kappes, J., Gottardo, R., Edlefsen, P., Self, S., Tang, H., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02853-13 · Cited by 330
“required for the PG9/PG16 epitope (46, 80), suggesting that resis-”
BackgroundSelf-citationBroadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Self-citationShingai, M., Donau, O. K., Plishka, R. J., Buckler-White, A., Mascola, J. R., Nabel, G. J., Nason, M. C., Montefiori, D., Moldt, B., Poignard, P., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132494 · Cited by 321
“…with the gp120 V1/V2, V3, and V4 regions, and the membrane proximal external region of gp41 (Walker et al., 2009, 2010, 2011a; Wu et al., 2010; McLellan et al., 2011; Scheid et al., 2011; Huang et al., 2012; Kong et al., 2013) and typically exhibit great breadth and potency against…”
BackgroundSelf-citationStructural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure
Kwong, P. D., & Mascola, J. R. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.029 · Cited by 304
Self-citationJulien, J.-P., Sok, D., Khayat, R., Lee, J. H., Doores, K. J., Walker, L. M., Ramos, A., Diwanji, D. C., Pejchal, R., Cupo, A., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003342 · Cited by 293
Self-citationXu, K., Acharya, P., Kong, R., Cheng, C., Chuang, G.-Y., Liu, K., Louder, M. K., O’Dell, S., Rawi, R., Sastry, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0042-6 · Cited by 283
“Antibody Fab and fusion peptide (residue 512–518) complexes were screened for crystallization from JCSG1–4 protein crystal screening kits using a Cartesian Honeybee crystallization robot as described previously 15 and a mosquito robot.”
Self-citationRudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02213-14 · Cited by 282
“HRV3C protease as described previously (22).”
Self-citationHorwitz, J. A., Halper-Stromberg, A., Mouquet, H., Gitlin, A. D., Tretiakova, A., Eisenreich, T. R., Malbec, M., Gravemann, S., Billerbeck, E., Dorner, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315295110 · Cited by 271
“S1); PG16, which recognizes the V1/V2 loop region (22, 31); and 10-1074, an antibody that targets the base of the V3 stem (19).”
BackgroundStructural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16
Pancera, M., Shahzad-ul-Hussan, S., Doria-Rose, N. A., McLellan, J. S., Bailer, R. T., Dai, K., Loesgen, S., Louder, M. K., Staupe, R. P., Yang, Y., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2600 · Cited by 270
Self-citationTrispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
Xu, L., Pegu, A., Rao, E., Doria-Rose, N., Beninga, J., McKee, K., Lord, D. M., Wei, R. R., Deng, G., Louder, M., et al. (2017) · Science · doi:10.1126/science.aan8630 · Cited by 270
Self-citationZolla-Pazner, S., deCamp, A., Gilbert, P. B., Williams, C., Yates, N. L., Williams, W. T., Howington, R., Fong, Y., Morris, D. E., Soderberg, K. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087572 · Cited by 267
Self-citationGlycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Chemoenzymatic Methods for the Synthesis of Glycoproteins
Li, C., & Wang, L.-X. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00238 · Cited by 250
Self-citationBehrens, A.-J., Vasiljevic, S., Pritchard, L. K., Harvey, D. J., Andev, R. S., Krumm, S. A., Struwe, W. B., Cupo, A., Kumar, A., Zitzmann, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.058 · Cited by 250
“…glycan structures (Blattner et al., 2014; Calarese et al., 2003; Falkowska et al., 2014; Garces et al., 2014; Huang et al., 2014; Kong et al., 2013; McLellan et al., 2011; Mouquet et al., 2012; Pancera et al., 2013; Pejchal et al., 2011; Scanlan et al., 2002; Scharf et al., 2014;Walker et al.,…”
BackgroundSelf-citationAsymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9
Julien, J.-P., Lee, J. H., Cupo, A., Murin, C. D., Derking, R., Hoffenberg, S., Caulfield, M. J., King, C. R., Marozsan, A. J., Klasse, P. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217537110 · Cited by 247
“Discussion It was shown that the PG9 bnAb is directed against an epitope in the V1/V2 region of gp120 (2, 32).”
BackgroundInfluentialSelf-citationThe HIV ‐1 envelope glycoprotein structure: nailing down a moving target
Ward, A. B., & Wilson, I. A. (2017) · Immunological Reviews · doi:10.1111/imr.12507 · Cited by 246
Self-citationPegu, A., Yang, Z.-Y., Boyington, J. C., Wu, L., Ko, S.-Y., Schmidt, S. D., McKee, K., Kong, W.-P., Shi, W., Chen, X., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008992 · Cited by 242
“PG9 represents one of a growing number of mAbs directed to HIV-1 envelope (Env) glycans (11, 19–21) and recognizes a conserved motif, including two glycans and a V1V2 peptide strand found on diverse viruses (22, 23).”
BackgroundSelf-citationDoria-Rose, N. A., Bhiman, J. N., Roark, R. S., Schramm, C. A., Gorman, J., Chuang, G.-Y., Pancera, M., Cale, E. M., Ernandes, M. J., Louder, M. K., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01791-15 · Cited by 241
“This category of antibodies typically relies on glycan residues, specifically, N156 and N160 in V2 (23).”
BackgroundInfluentialSelf-citationLee, J. H., Andrabi, R., Su, C.-Y., Yasmeen, A., Julien, J.-P., Kong, L., Wu, N. C., McBride, R., Sok, D., Pauthner, M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.017 · Cited by 239
“Examples of patient-derived bnAbs that belong to this class include PG9, PG16, CH01-CH04, the CAP256-VRC26 lineage, PGT141-145, and PGDM1400-1412 (Doria-Rose et al., 2014; McLellan et al., 2011; Sok et al., 2014; Walker et al., 2011; Walker et al., 2009).”
BackgroundMethodInfluentialSelf-citationStructure-Based Vaccine Antigen Design
Graham, B. S., Gilman, M. S. A., & McLellan, J. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-121217-094234 · Cited by 234
Self-citationGottardo, R., Bailer, R. T., Korber, B. T., Gnanakaran, S., Phillips, J., Shen, X., Tomaras, G. D., Turk, E., Imholte, G., Eckler, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075665 · Cited by 234
“These linear epitopes are presumably unrelated to most broadly neutralizing Abs that bind discontinuous conformation-dependent epitopes [7-18].”
BackgroundMethodInfluentialSelf-citationGeneration of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Lewis, S. M., Wu, X., Pustilnik, A., Sereno, A., Huang, F., Rick, H. L., Guntas, G., Leaver-Fay, A., Smith, E. M., Ho, C., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2797 · Cited by 234
Wang, F., Ekiert, D. C., Ahmad, I., Yu, W., Zhang, Y., Bazirgan, O., Torkamani, A., Raudsepp, T., Mwangi, W., Criscitiello, M. F., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.049 · Cited by 223
“In humans, some longer CDR H3 loops with unusual protruding structures have been described that contribute to important functions such as virus neutralization (Collis et al., 2003; Kwong and Wilson, 2009; Pejchal et al., 2010; Saphire et al., 2001; McLellan et al., 2011; Ekiert et al., 2012).”
Self-citationLiu, H., Wu, N. C., Yuan, M., Bangaru, S., Torres, J. L., Caniels, T. G., van Schooten, J., Zhu, X., Lee, C.-C. D., Brouwer, P. J. M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.023 · Cited by 214
“Some pertinent examples are the antibodies PG9 and PG16, whose CDR H3s interact extensively along their length with the apex of the HIV-1 Envelope protein (McLellan et al., 2011; Pan et al., 2020).”
Self-citationMurin, C. D., Wilson, I. A., & Ward, A. B. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0392-y · Cited by 213
Self-citationLee, P. S., Ohshima, N., Stanfield, R. L., Yu, W., Iba, Y., Okuno, Y., Kurosawa, Y., & Wilson, I. A. (2014) · Nature Communications · doi:10.1038/ncomms4614 · Cited by 213
Self-citationIdentification and specificity of broadly neutralizing antibodies against HIV
McCoy, L. E., & Burton, D. R. (2017) · Immunological Reviews · doi:10.1111/imr.12484 · Cited by 213
Self-citationAntibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike
Scharf, L., Scheid, J. F., Lee, J. H., West, A. P., Chen, C., Gao, H., Gnanapragasam, P. N. P., Mares, R., Seaman, M. S., Ward, A. B., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.001 · Cited by 212
“CDRH3 residues corresponding to 8ANC195HC residues 90–105 (pink) of NIH45-46 (blue; PDB 3U7Y), PG16 (gray; PDB 4DQO), PGT121 (purple; PDB 4FQC), and PGT128 (orange; PDB 3TYG) are shown as Ca traces.”
BackgroundInfluentialSelf-citationDelineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization
Georgiev, I. S., Doria-Rose, N. A., Zhou, T., Do Kwon, Y., Staupe, R. P., Moquin, S., Chuang, G.-Y., Louder, M. K., Schmidt, S. D., Altae-Tran, H. R., et al. (2013) · Science · doi:10.1126/science.1233989 · Cited by 212
Self-citationHIV entry and envelope glycoprotein-mediated fusion
Blumenthal, R., Durell, S., & Viard, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.406272 · Cited by 212
Karasavvas, N., Billings, E., Rao, M., Williams, C., Zolla-Pazner, S., Bailer, R. T., Koup, R. A., Madnote, S., Arworn, D., Shen, X., et al. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0103 · Cited by 211
“The structure of scaffolded V1/V2 complexed with the broadly neutralizing monoclonal antibody PG9 has been resolved.(47) This potent antibody binds to glycans and aa sequences within the V1/V2 regions.”
BackgroundInfluentialSelf-citationStructural and molecular basis for Ebola virus neutralization by protective human antibodies
Misasi, J., Gilman, M. S. A., Kanekiyo, M., Gui, M., Cagigi, A., Mulangu, S., Corti, D., Ledgerwood, J. E., Lanzavecchia, A., Cunningham, J., et al. (2016) · Science · doi:10.1126/science.aad6117 · Cited by 211
Self-citationGlobal site-specific N-glycosylation analysis of HIV envelope glycoprotein
Cao, L., Diedrich, J. K., Kulp, D. W., Pauthner, M., He, L., Park, S.-K. R., Sok, D., Su, C. Y., Delahunty, C. M., Menis, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14954 · Cited by 207
“Previous structural studies have suggested that a sialylated glycan present at site N156 plays a key role for PG9/ PG16 binding 13,57 , so it was surprising that this site was mainly occupied by high-mannose structures.”
Self-citationUltrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Wang, L., Zhou, T., Zhang, Y., Yang, E. S., Schramm, C. A., Shi, W., Pegu, A., Oloniniyi, O. K., Henry, A. R., Darko, S., et al. (2021) · Science · doi:10.1126/science.abh1766 · Cited by 206
“The SARSCoV-2 S-2P (VRC-SARS-CoV-2 S-2P (15-1208)3C-His8-Strep2x2) andRBD (Ragon-SARS-CoV-2 S-RBD (319-529)-His8-SBP) Antigen are coated onto Immulon 4HBX flat bottom plates overnight for 16 hours at 4°C at a concentration of 2 mg/ml and 4mg/ml, respectively.”
MethodSelf-citationGristick, H. B., von Boehmer, L., West Jr, A. P., Schamber, M., Gazumyan, A., Golijanin, J., Seaman, M. S., Fätkenheuer, G., Klein, F., Nussenzweig, M. C., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3291 · Cited by 200
Andrabi, R., Voss, J. E., Liang, C.-H., Briney, B., McCoy, L. E., Wu, C.-Y., Wong, C.-H., Poignard, P., & Burton, D. R. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.014 · Cited by 192
“Since PG9 LC somatic mutations were essential for antibody neutralizing activity (Figure 4B, C), we hypothesized that combining the somatic mutations in VH with VL mutations might have a complementary effect, especially residues E37, S38 and D56 that are critical for glycan recognition (McLellan et al., 2011; Pancera…”
InfluentialSelf-citationWagh, K., Bhattacharya, T., Williamson, C., Robles, A., Bayne, M., Garrity, J., Rist, M., Rademeyer, C., Yoon, H., Lapedes, A., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005520 · Cited by 191
Self-citationMedina-Ramírez, M., Garces, F., Escolano, A., Skog, P., de Taeye, S. W., Del Moral-Sanchez, I., McGuire, A. T., Yasmeen, A., Behrens, A.-J., Ozorowski, G., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161160 · Cited by 190
“We hypothesize that this flexible region 341 inhibits interactions with HCDR3 of mature and precursor bNAbs, such as PG9, and 342 therefore the 7 amino-acid deletion in this region of V2 in the GT1 trimer might 343 alleviate that inhibition.”
BackgroundMethodInfluentialSelf-citationWibmer, C. K., Bhiman, J. N., Gray, E. S., Tumba, N., Abdool Karim, S. S., Williamson, C., Morris, L., & Moore, P. L. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003738 · Cited by 185
Sok, D., Doores, K. J., Briney, B., Le, K. M., Saye-Francisco, K. L., Ramos, A., Kulp, D. W., Julien, J.-P., Menis, S., Wickramasinghe, L., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008104 · Cited by 183
Self-citationRecombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
Hoot, S., McGuire, A. T., Cohen, K. W., Strong, R. K., Hangartner, L., Klein, F., Diskin, R., Scheid, J. F., Sather, D. N., Burton, D. R., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003106 · Cited by 184
Self-citationPresenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles
He, L., de Val, N., Morris, C. D., Vora, N., Thinnes, T. C., Kong, L., Azadnia, P., Sok, D., Zhou, B., Burton, D. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms12041 · Cited by 182
“Our results demonstrate that the V1V2 region of HIV-1 Env can be presented in a native-like trimeric conformation on FR nanoparticle.”
InfluentialSelf-citationSok, D., Laserson, U., Laserson, J., Liu, Y., Vigneault, F., Julien, J.-P., Briney, B., Ramos, A., Saye, K. F., Le, K., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003754 · Cited by 184
“involvement of other glycans in neutralization [5,7,42–44].”
Self-citationZolla-Pazner, S., deCamp, A. C., Cardozo, T., Karasavvas, N., Gottardo, R., Williams, C., Morris, D. E., Tomaras, G., Rao, M., Billings, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053629 · Cited by 183
Self-citationEarly Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape
Bar, K. J., Tsao, C.-Y., Iyer, S. S., Decker, J. M., Yang, Y., Bonsignori, M., Chen, X., Hwang, K.-K., Montefiori, D. C., Liao, H.-X., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002721 · Cited by 180
“. This model lacked only the V1/V2 region, and escape mutations in V1/V2 were thus modeled with the scaffolded structure of V1/V2”
MethodSelf-citationStructural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies
Garces, F., Sok, D., Kong, L., McBride, R., Kim, H. J., Saye-Francisco, K. F., Julien, J.-P., Hua, Y., Cupo, A., Moore, J. P., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.009 · Cited by 178
“, 2009), which both recognize N156 and N160 in V1/V2, but PG9 has evolved a preference for N160, whereas PG16 favors N156 (McLellan et al., 2011; Pancera et al., 2013).”
Self-citationGorman, J., Soto, C., Yang, M. M., Davenport, T. M., Guttman, M., Bailer, R. T., Chambers, M., Chuang, G.-Y., DeKosky, B. J., Doria-Rose, N. A., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3144 · Cited by 177
Self-citationHIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Bricault, C. A., Yusim, K., Seaman, M. S., Yoon, H., Theiler, J., Giorgi, E. E., Wagh, K., Theiler, M., Hraber, P., Macke, J. P., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2018.12.001 · Cited by 178
Self-citationQuantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation
Zhou, T., Doria-Rose, N. A., Cheng, C., Stewart-Jones, G. B. E., Chuang, G.-Y., Chambers, M., Druz, A., Geng, H., McKee, K., Kwon, Y. D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.013 · Cited by 176
“Analysis of known broadly neutralizing HIV-1 antibodies reveals that many of these rare antibodies require recognition of N-linked glycan for high affinity binding (McLellan et al., 2011; Pejchal et al., 2011; Walker et al., 2011; Walker et al., 2009).”
BackgroundSelf-citationElshabrawy, H. A., Coughlin, M. M., Baker, S. C., & Prabhakar, B. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050366 · Cited by 172
“Our findings are not only relevant to designing a highly effective passive therapy for SARS-CoV but have implications for the development of passive therapy for other viral infections including influenza and HIV [38, 39, 43] .”
BackgroundStructural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
Zhou, T., Wang, L., Misasi, J., Pegu, A., Zhang, Y., Harris, D. R., Olia, A. S., Talana, C. A., Yang, E. S., Chen, M., et al. (2022) · Science · doi:10.1126/science.abn8897 · Cited by 170
Self-citationCATNAP: a tool to compile, analyze and tally neutralizing antibody panels
Yoon, H., Macke, J., West, A. P., Foley, B., Bjorkman, P. J., Korber, B., & Yusim, K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv404 · Cited by 168
HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120
Kovacs, J. M., Nkolola, J. P., Peng, H., Cheung, A., Perry, J., Miller, C. A., Seaman, M. S., Barouch, D. H., & Chen, B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204533109 · Cited by 169
Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development
Bonsignori, M., Liao, H., Gao, F., Williams, W. B., Alam, S. M., Montefiori, D. C., & Haynes, B. F. (2017) · Immunological Reviews · doi:10.1111/imr.12509 · Cited by 168
Self-citationChemical and Chemoenzymatic Synthesis of Glycoproteins for Deciphering Functions
Wang, L.-X., & Amin, M. N. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.01.001 · Cited by 163
“…glycan at Asn-160 for recognition by antibody PG9 and PG16, and further revealed a critical role of a sialylated N-glycan at the secondary glycosylation site (Asn-156 or Asn173) for high affinity binding, which was not revealed by the original PG9 structural study (McLellan et al., 2011).”
BackgroundInfluentialSelf-citationKam, Y.-W., Lee, W. W. L., Simarmata, D., Harjanto, S., Teng, T.-S., Tolou, H., Chow, A., Lin, R. T. P., Leo, Y.-S., Rénia, L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01780-12 · Cited by 161
“interactions between specific antibodies and corresponding peptides at the amino acid level (22), providing key information in optimizing CHIKV vaccine development with important specific amino acid residues in anti-CHIKV antibody recognition.”
BackgroundSynthetically defined glycoprotein vaccines: current status and future directions
Adamo, R., Nilo, A., Castagner, B., Boutureira, O., Berti, F., & Bernardes, G. J. L. (2013) · Chemical Science · doi:10.1039/c3sc50862e · Cited by 158
Implications of HIV diversity for the HIV-1 pandemic
Hemelaar, J. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.10.026 · Cited by 189
Hu, J. K., Crampton, J. C., Cupo, A., Ketas, T., van Gils, M. J., Sliepen, K., de Taeye, S. W., Sok, D., Ozorowski, G., Deresa, I., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01653-15 · Cited by 155
“The bnAbs used to evaluate the epitope specificities of the mouse sera were PGT145, specific for the apex (V1V2 Asn160) (63), PGT128, specific for the high-mannose patch V3 glycan (29), PGT135, specific for a lower region of the high-mannose patch (64), VRC01, specific for the CD4 binding site (65), PGT151 (66) and 35…”
MethodSelf-citationKlein, F., Gaebler, C., Mouquet, H., Sather, D. N., Lehmann, C., Scheid, J. F., Kraft, Z., Liu, Y., Pietzsch, J., Hurley, A., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120423 · Cited by 179
“In addition, PG9 and PG16 target epitopes on the variable loops (Walker et al., 2009; Davenport et al., 2011; McLellan et al., 2011) that are also seen by the strain-specific antibody 2909 (Gorny et al., 2005) and the antibodies CH1-CH4 (Bonsignori et al., 2011).”
BackgroundSubunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer
Mao, Y., Wang, L., Gu, C., Herschhorn, A., Xiang, S.-H., Haim, H., Yang, X., & Sodroski, J. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2351 · Cited by 160
“The PG16 neutralizing antibody recognizes a gp120 epitope that is very sensitive to changes in the V1/V2 and V3 variable regions, in the associated glycans, and in the quaternary structure of the Env trimer 30,46 .”
Self-citationHerschhorn, A., Ma, X., Gu, C., Ventura, J. D., Castillo-Menendez, L., Melillo, B., Terry, D. S., Smith, A. B., Blanchard, S. C., Munro, J. B., et al. (2016) · mBio · doi:10.1128/mbio.01598-16 · Cited by 150
Tools to therapeutically harness the human antibody response
Wilson, P. C., & Andrews, S. F. (2012) · Nature Reviews Immunology · doi:10.1038/nri3285 · Cited by 147
“In this way, they obtained broadly neutralizing antibodies that recognized conserved glycan-protein quarternary structures in variable loop regions of gp120 that were thought to be poor targets for broadly neutralizing antibodies owing to their mostly variable residues 27, 85, 87 .”
Background
Metadata
- Authors
- McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon, Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., & Kwong, P. D.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Scripps Research Institute (US)
- Duke University (US)
- Tumaini University (TZ)
- International AIDS Vaccine Initiative (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Kwong, Peter D.
- ORCID
- McLellan, Jason S.
- Pancera, Marie
- Carrico, Chris
- Gorman, Jason
- Julien, Jean-Philippe
- Khayat, Reza
- Louder, Robert
- Patel, Nikita
- Yang, Yongping
- Zhang, Baoshan
- Zhou, Tongqing
- Zhu, Jiang
- Boyington, Jeffrey C.
- Chuang, Gwo-Yu
- Diwanji, Devan
- Georgiev, Ivelin
- Louder, Mark K.
- Moquin, Stephanie
- Schmidt, Stephen D.
- Bonsignori, Mattia
- Crump, John A.
- Kapiga, Saidi H.
- Haynes, Barton F.
- Burton, Dennis R.
- Koff, Wayne C.
- Walker, Laura M.
- Wyatt, Richard
- Wang, Lai-Xi
- Arthos, James
- Bewley, Carole A.
- Mascola, John R.
- Nabel, Gary J.
- Schief, William R.
- Ward, Andrew B.
- Wilson, Ian A.
- Kwong, Peter D.
- Venue
- Nature
- Published
- 2011-11-23
- Volume
- 480
- Issue
- 7377
- Pages
- 336-343
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3406929
- OpenAlex
- W2122617162
- Cited by
- 830
- References
- 69
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 36 · 2021: 38 · 2020: 39 · 2019: 52 · 2018: 63 · 2017: 70 · 2016: 64 · 2015: 84 · 2014: 92 · 2013: 120 · 2012: 78
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Energy (W - 31 - 109 - Eng - 38)
- International AIDS Vaccine Initiative
- Ragon Institute of MGH, MIT and Harvard
- National Institutes of Health
- Office of Science (W-31-109-ENG-38)
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- National Center for Research Resources (RR017573, P41RR017573)
- Basic Energy Sciences (W-31-109-Eng38)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- HIV-1 gp120, antibody-antigen complex structure, N-glycosylation, carbohydrate recognition, HIV vaccine development, envelope glycoprotein
- MeSH terms
- Amino Acid Sequence, Antibody Affinity, Antibody Specificity, Antigen-Antibody Complex, Epitopes, Binding Sites, Antibody, Glycopeptides, Glycosylation, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Polysaccharides, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, AIDS Vaccines, Conserved Sequence, Protein Structure, Tertiary, Crystallography, X-Ray, Amino Acid Motifs, Protein Structure, Quaternary, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.